Wolfgang P. Fendler

Essen University Hospital — Germany

Medicine · Health Sciences

60h-index16.2kcitations550works4.72yr avg
OpenAlex↗ORCID↗Google Scholar↗Lab page↗

Accepting Students?

No reports yet. Know if this professor is taking students?

Research Topics

Prostate Cancer Treatment and Research(265), Radiopharmaceutical Chemistry and Applications(233), Medical Imaging Techniques and Applications(132), Prostate Cancer Diagnosis and Treatment(115), Peptidase Inhibition and Analysis(87)

Publications548 total

Prognostic parameters and detection of cardiac amyloidosis with hybrid 18F-Florbetaben-PET/MRI: an exploratory observational study
European Journal of Nuclear Medicine and Molecular Imaging·2026Open Access
Treatment response assessment according to updated PROMISE criteria
Seminars in Nuclear Medicine·2025Open Access
The value of PSMA PET for risk stratification in prostate cancer: an update and future aspects
Seminars in Nuclear Medicine·2025Open Access
New targets of PET imaging for renal cancer
Seminars in Nuclear Medicine·2025Open Access
Prostate-specific Membrane Antigen Positron Emission Tomography Versus Conventional Imaging for Preoperative Staging High-risk Prostate Cancer Patients Undergoing Surgery for cN0M0 Disease: An European Association of Urology—Young Academic Urologists Prostate Cancer Working Group Multi-institutional Study
European Urology Oncology·2025
Potential value of [68Ga]Ga-FAPI-46 PET in patients with metastatic urothelial carcinoma: a bi-centric analysis
European Journal of Nuclear Medicine and Molecular Imaging·2025Open Access
Prognostische waarde van PSMA PET/CT in het voorspellen van de biochemisch recidiefvrije overleving na radicale prostatectomie in miN0-patiënten
Tijdschrift voor Urologie·2025Open Access
[ <sup>68</sup> Ga]Ga-FAPI-46 PET/CT of Patients with Gastrointestinal Stromal Tumors in Comparison to 2-[ <sup>18</sup> F]FDG PET/CT and Contrast-Enhanced CT: Results from a Prospective Observational Study
Journal of Nuclear Medicine·2025
[18F]FDG-PET/CT-based evaluation of tumor response kinetics during induction chemotherapy and concurrent radiochemotherapy in stage II - III small-cell lung cancer
European Journal of Nuclear Medicine and Molecular Imaging·2025Open Access
Somatostatin analogs in neuroendocrine tumors with <scp>Ki‐67</scp> index of ≥10%
Journal of Neuroendocrinology·2025Open Access
Hormonsyndrome bei neuroendokrinen Tumoren
Die Gastroenterologie·2025
Rechallenge and Extended [ <sup>177</sup> Lu]Lu-PSMA Therapy in Metastatic Prostate Cancer
Journal of Nuclear Medicine·2025· 1 cited
ESUR: Opportunities for PSMA-PET/CT and whole-body MRI in advanced prostate cancer
European Radiology·2025· 3 citedOpen Access
Pathologic Complete Response Predicts Long‐Term Survival Following Neoadjuvant Induction Chemotherapy and Chemo‐Radiotherapy in Stage‐ <scp>III</scp> Non‐Small Cell Lung Cancer
Thoracic Cancer·2025Open Access
Clinical Impact of Changes in Tumor Uptake and Volume on PSMA PET/CT During [ <sup>177</sup> Lu]Lu-PSMA Therapy in Metastatic Castration-Resistant Prostate Cancer
Journal of Nuclear Medicine·2025
Association Between the PRIMARY Score at Staging Prostate-specific Membrane Antigen Positron Emission Tomography and Overall Survival Among Patients with Newly Diagnosed Prostate Cancer: Findings from the International, Multicenter PROMISE Registry
European Urology·2025· 2 citedOpen Access
High incidence and poor prognosis of bone metastases in functioning small intestinal neuroendocrine tumors
Frontiers in Endocrinology·2025Open Access
Prostate‐specific membrane antigen positron emission tomography/computed tomography imaging as a precision diagnostic at prostate cancer recurrence after radical prostatectomy: Modeling long‐term survival
Cancer·2025
Thyroid Hormone Withdrawal Yields Higher <sup>131</sup> I Absorbed Dose to Metastases Than rhTSH Stimulation in Differentiated Thyroid Cancer: Evidence from a Large <sup>124</sup> I PET/CT Dosimetry Cohort
Journal of Nuclear Medicine·2025
Fully Automated Image-Based Multiplexing of Serial PET/CT Imaging for Facilitating Comprehensive Disease Phenotyping
Journal of Nuclear Medicine·2025· 2 cited
page 1 of 28Next →

Frequent Co-authors

Ken Herrmann(28), Jérémie Calais(26), Matthias Eiber(21), Johannes Czernin(16), Thomas A. Hope(16), Peter Bartenstein(10), Robert E. Reiter(10), Matthew B. Rettig(10), Matthias Eiber(9), Clemens Kratochwil(8), Uwe Haberkorn(8), Tobias Maurer(8), Michael S. Hofman(8), Manuel Weber(8), Harun Ilhan(7), Christoph Rischpler(7), Francesco Ceci(7), Boris Hadaschik(7), Isabel Rauscher(7), Kambiz Rahbar(6)